Arcus Biosciences Inc

RCUS

New York Stock Exchange. Currency in USD

30.51 -0.38 ( -1.23% )

Real time prices: December 19

Market Cap.
2.21B
Beta (5Y monthly)
0.70
Price/Earnings
33.03
EPS (TTM)
0.92
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
1.31M
1y Target Est.
45.83
Day's Range
28.26
-
31.14
52 Week's Range
16.74
-
39.75

Historical Summary

Performance
EPS growth
Share Buybacks

About Arcus Biosciences Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.arcusbio.com
Exchange
New York Stock Exchange (XNYS)
Shares Outstanding
70.25M
Employees
366
Address
3928 Point Eden Way, Hayward, CA, United States, 94545
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.

Latest news

Gilead (GILD), RCUS Announce Positive Data From NSCLC Study
Gilead (GILD), RCUS Announce Positive Data From NSCLC Study

Gilead (GILD) and RCUS release encouraging data from the fourth interim analysis of the phase...
By Zacks Investment Research - 8 weeks ago

Wall Street Analysts Believe Arcus Biosciences, Inc. (RCUS) Could Rally 45%: Here's is How to Trade
Wall Street Analysts Believe Arcus Biosciences, Inc. (RCUS) Could Rally 45%: Here's is How to Trade

The consensus price target hints at a 44.5% upside potential for Arcus Biosciences, Inc. (RCUS)....
By Zacks Investment Research - 8 weeks ago

Expert Ratings for Arcus Biosciences
Expert Ratings for Arcus Biosciences

Over the past 3 months, 4 analysts have published their opinion on Arcus Biosciences (NYSE:RCUS)...
By Benzinga - 9 weeks ago

Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022

Upgrades According to Summit Insights Group, the prior rating for Applied Materials Inc (NASDAQ:AMAT) was...
By Benzinga - 10 weeks ago

Wall Street Analysts See a 75% Upside in Arcus Biosciences, Inc. (RCUS): Can the Stock Really Move This High?
Wall Street Analysts See a 75% Upside in Arcus Biosciences, Inc. (RCUS): Can the Stock Really Move This High?

The consensus price target hints at a 75% upside potential for Arcus Biosciences, Inc. (RCUS)....
By Zacks Investment Research - 11 weeks ago

Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 14.29% and 83.94%, respectively, for...
By Zacks Investment Research - 12 weeks ago

Alkermes (ALKS) Q3 Earnings Meet Estimates, Revenues Miss
Alkermes (ALKS) Q3 Earnings Meet Estimates, Revenues Miss

Alkermes' (ALKS) earnings meet estimates in the third quarter of 2022 while revenues miss the...
By Zacks Investment Research - 12 weeks ago

Novo Nordisk's (NVO) Q3 Earnings & Revenues Beat Estimates
Novo Nordisk's (NVO) Q3 Earnings & Revenues Beat Estimates

Novo Nordisk (NVO) reports better-than-expected Q3 results. Sales are aided by growth in Diabetes and...
By Zacks Investment Research - 12 weeks ago